APA (7th ed.) Citation

L, P., C, Y., DM, W., HS, H., L, D., AM, W., . . . LJ, E. (2021). Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer cell, 39(7), 989. https://doi.org/10.1016/j.ccell.2021.05.009

Chicago Style (17th ed.) Citation

L, Pusztai, et al. "Durvalumab with Olaparib and Paclitaxel for High-risk HER2-negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Trial." Cancer Cell 39, no. 7 (2021): 989. https://doi.org/10.1016/j.ccell.2021.05.009.

MLA (9th ed.) Citation

L, Pusztai, et al. "Durvalumab with Olaparib and Paclitaxel for High-risk HER2-negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Trial." Cancer Cell, vol. 39, no. 7, 2021, p. 989, https://doi.org/10.1016/j.ccell.2021.05.009.